Dergiler / Southern Clinics of Istanbul Eurasia / 2021 / Cilt: 32 - Sayı: 1

Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents

Sayfa
19–24
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Awareness of hepatitis B and TB reactivation risk in patients treated with biologic agents was greater than awareness of the risk of other infections.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Biologic agents can provide effective control of disease activity in patients with chronic inflammatory disease (CID), however, they are associated with an increased risk of serious infection.
📊
Temel Bulgular & Veri:The aim of this study was to investigate the risk and distribution of serious infection, the rate of vaccination, and the screening tests recommended in patients treated with biologic agents.
💡
Sonuç & Katkı:Awareness of hepatitis B and TB reactivation risk in patients treated with biologic agents was greater than awareness of the risk of other infections.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Biologic agents can provide effective control of disease activity in patients with chronic inflammatory disease (CID), however, they are associated with an increased risk of serious infection. The aim of this study was to investigate the risk and distribution of serious infection, the rate of vaccination, and the screening tests recommended in patients treated with biologic agents. Methods: Patients with CID who were given biologic agent therapy were retrospectively evaluated. Hepatitis and tuberculosis (TB) screening tests, the vaccinations administered, risk factors for and the rate of serious infection were reviewed. Results: Of the 320 patients included in the study, 58% were male and the mean age was 44.5 years (±12.2 years). The biologic agent used was infliximab in 108 patients (33.8%), adalimumab in 115 (35.9%), etanercept in 61 (19.1%), ustekinumab in 19 (5.9%), certolizumab in 9 (2.8%), golimumab in 5 (1.6%), and secukinumab in 3 (0.9%). The hepatitis B, pneumococcal, influenza, and hepatitis A vaccination rate in patients with CID was 82.9%, 12.5%, 11.6%, and 4%, respectively. The tuberculin skin test was preferred for 33.4% of the patients for TB screening, while the QuantiFERON-TB Gold test (Qiagen NV, Hilden, Germany) was used in 79%. A total of 25 (7.8%) cases of serious infection occurred, and the most common sites were the respiratory tract (28%) and the urinary tract (28%). Binary logistic regression analysis showed that the risk of infection was significantly higher in patients who had chronic obstructive pulmonary disease (COPD) and those who used azathioprine. Conclusion: The most common sites of infection were the respiratory tract and the urinary tract, and the risk of infection was significantly higher in patients who had COPD and those who used azathioprine. The rate of vaccination was lower than has been recommended. Awareness of hepatitis B and TB reactivation risk in patients treated with biologic agents was greater than awareness of the risk of other infections.

🔖

Bu Makaleye Atıf Yap

OKAY, G., KESKİN, E. B. (2021). Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents. Southern Clinics of Istanbul Eurasia, Cilt: 32 - Sayı: 1, 19–24. https://ajindex.com/articles/313945

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Quartuccio L, Zabotti A, Del Zotto S, Zanier L, De Vita S, Valent F. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data. J Adv Res 2018
  2. 87–93 2. Pecoraro V, De Santis E, Melegari A, Trenti T. The impact of immunogenicity of TNFα inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis. Autoimmun Rev 2017
  3. 564–75. 3. Krulig E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid 2010
  4. 11–22. 4. Reszke R, Szepietowski JC. Secukinumab in the treatment of psoriasis: an update. Immunotherapy 2017
  5. 229–38. 5. Ergun T, Seckin D, Baskan Bulbul E, Onsun N, Ozgen Z, Unalan P, et al. The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents. Int J Dermatol 2015
  6. 594–9. 6. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A
  7. B S R B R Control Centre Consortium, Symmons DP
  8. BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010
  9. 522–8. 7. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al
  10. Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009
  11. 1884–94 8. Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccinepreventable illnesses. Am J Gastroenterol 2006
  12. 1834–40. 9. Ford AC, Peyrin-Biroulet L. Opportunistic infections with antitumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013
  13. 1268–76. 10. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2017
  14. 241–58. 11. CDC: Recommended immunization schedule for adults aged 19 years or older, United States, 2018. Available at: https://www.cdc. gov/vaccines/schedules/hcp/imz/adult.html. Accessed Feb 15, 2021. 12. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al
  15. Infectious Diseases Society o